Xeltis makes first commercial implant of aXess vascular access device
Xeltis has completed the first commercial implantation of its aXess vascular access device, marking the start of the Dutch company's European commercial launch. The procedure was performed by Dr Dominik Liebetrau, Head of Vascular Surgery at Artemed Klinikum Munich South, Germany, on 7 July 2026.
aXess is designed as a single-procedure implant that initially functions as a scaffold for haemodialysis cannulation before gradually transforming into the patient's own living vessel through vascular cell ingrowth and tissue regeneration. Xeltis describes the underlying science as grounded in Nobel Prize-winning supramolecular chemistry, delivered through its proprietary Restorex polymer platform. The implant is eventually absorbed, leaving newly formed autologous-like tissue in place.
Clinical and commercial backdrop
The commercial launch follows twelve-month European pivotal trial data that Xeltis says demonstrated secondary patency comparable to matured arteriovenous fistulas (AVFs), alongside lower reintervention rates and superior infection resistance relative to historical arteriovenous graft (AVG) benchmarks. The device received CE mark approval ahead of the launch, though the company did not specify the exact approval date in its announcement.
Dr Liebetrau said the device "integrated seamlessly into our existing surgical workflow" and described it as providing "a fundamentally new approach to vascular access." Eliane Schutte, chief executive of Xeltis, framed the implantation as "the transition from clinical development into routine patient care," adding that the European rollout lays the foundation for broader adoption across the continent and, ultimately, in the United States.
Xeltis is simultaneously running a US pivotal trial of aXess and confirmed that enrolment has now exceeded 50%, a meaningful step towards a potential FDA submission. The company has not disclosed an expected enrolment completion date or a regulatory timeline for the US market.
Market context and competitive landscape
Vascular access for haemodialysis represents a substantial and underserved clinical need. Approximately 3.5 million people worldwide receive haemodialysis for end-stage kidney disease, and the adequacy of vascular access is a primary driver of patient morbidity and quality of life. The dominant options today remain the autologous AVF and the synthetic AVG, both of which carry well-documented limitations: AVFs require maturation time of several weeks and fail to develop in a sizeable proportion of patients, while AVGs carry higher infection risk and frequent reintervention.
The regenerative vascular access space has attracted a small but growing number of academic spinouts and device companies pursuing bioresorbable or tissue-engineered conduits. Xeltis's investor base, which includes DaVita Venture Group, EQT Life Sciences, Kurma Partners and the European Innovation Council, is notable: DaVita is one of the world's largest haemodialysis operators, giving Xeltis a strategic commercial partner with direct access to the patient population the device targets.
The company's ability to demonstrate durability data beyond twelve months and to build a reimbursement pathway in major European markets will be closely watched. Germany's early role as a commercial launch site is strategically sensible, given its historically receptive reimbursement environment for novel medical devices under the NUB (Neue Untersuchungs- und Behandlungsmethoden) transitional payment mechanism. Broader European adoption will depend on health technology assessment outcomes that have yet to be reported.